Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs BlackRock TCP Capital Corp — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while BlackRock TCP Capital Corp trades at $4.07 (market cap $342.32M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 21.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.63% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and BlackRock TCP Capital Corp for 89 Days on average.
| SYRE | TCPC | |
|---|---|---|
Market Cap | $7.35B | $342.32M |
Volume | 1,624,631 | 916,536 |
Sector | Health | Financials |
52-Week High | $108.92 | $6.20 |
52-Week Low | $22.18 | $3.13 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $6.35B | $1.10B |
Dividend Yield | — | 18.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TCPC trades at $3.98 with no recent price movement. The stock shows a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, the company reported negative revenue and net income for 2025, with declining trends projected into 2026. Recent positive developments include Q2 2026 earnings beats and a $523 million portfolio sale that reduced leverage. Analyst sentiment is mixed with 30.77% buy ratings but 69.23% hold recommendations.
TCPC presents a complex investment case with attractive valuation metrics including P/B of 0.62 suggesting potential undervaluation, but significant fundamental challenges with negative revenue and profitability trends. The strategic portfolio sale and ongoing business review offer potential catalysts, though investors face risks from the class action lawsuit and persistent negative cash flow. The dividend yield remains a positive factor for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
